1. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. (16th November 2017) Authors: Yoshino, T; Arnold, D; Taniguchi, H; Pentheroudakis, G; Yamazaki, K; Xu, R -H; Kim, T W; Ismail, F; Tan, I B; Yeh, K -H; Grothey, A; Zhang, S; Ahn, J B; Mastura, M Y; Chong, D; Chen, L -T; Kopetz, S; Eguchi-Nakajima, T; Ebi, H; Ohtsu, A Journal: Annals of oncology Issue: Volume 29:Number 1(2018) Page Start: 44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 607TiPBIG BANG study: A multicenter phase II study of the MEK inhibitor binimetinib + BRAF inhibitor encorafenib + anti-EGFR antibody cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (EPOC 1703). (23rd October 2018) Authors: Kotani, D; Bando, H; Masuishi, T; Komatsu, Y; Yamaguchi, K; Nakajima, T E; Satoh, T; Nishina, T; Esaki, T; Nomura, S; Sakamoto, S; Iida, S; Matsuda, S; Yonemura, M; Fuse, N; Sato, A; Fujii, S; Ebi, H; Ohtsu, A; Yoshino, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗